| Abstrakt: |
A recent study conducted by researchers at the University of North Texas Health Science Center has explored potential targets for natural killer (NK) cell immunotherapy against glioblastoma multiforme (GBM), the most common type of primary malignant brain tumor. The study highlights the dismal overall survival rate of GBM and the lack of successful therapies beyond surgical resection, radiation, and chemotherapy. The researchers propose investigating targets such as EGFR, HER2, CD155, IL-13Ra2, Lectin-like Transcript 1 (LLT1), and cell surface proliferating cell nuclear antigen (csPCNA) for NK cell-based immunotherapy. This research contributes to the ongoing efforts to implement immunotherapy in GBM treatment. [Extracted from the article] |
